Development and Validation of a Method for Simultaneous Estimation of Bupropion and Dextromethorphan Using Reverse Phase High Performance Liquid Chromatography in Active Pharmaceutical Ingredient Form

P. Sugandha Kumar

Department of Chemistry, RVR & JC College of Engineering, Chowdavaram, Guntur-522019, Andhra Pradesh, India.

Kantipudi Rambabu *

Department of Chemistry, RVR & JC College of Engineering, Chowdavaram, Guntur-522019, Andhra Pradesh, India.

*Author to whom correspondence should be addressed.


Aims: New validated method for the simultaneous estimation of Bupropion and Dextromethorphan using HPLC.

Place and Duration of Study: Department of Chemistry, RVR & JC College of Engineering, Chowdavaram, Guntur, Andhra Pradesh, between July 2022 and August 2022.

Methodology: Using Inertsil ODS 250 x 4.6 mm, 5 µm column, acetonitrile and 0.1 percent formic acid (30:70 v/v) as a mobile phase, the proposed method successfully achieved effective chromatographic separation with a flow rate of 1 mL/min and a wave length of 240 nm. The Bupropion and Dextromethorphan peaks were resolved within 5 minutes of elution time, with the Bupropion peak eluting at 2.054 minutes and the Dextromethorphan peak eluting at 3.940 minutes.

Results: The proposed method displays excellent linearity in the concentration ranges of 52.5-315 µg/mL for Bupropion and 22.5-135 µg/mL for Dextromethorphan. The RSD of robustness levels has a maximum of just 2 percent.

Conclusion: The accuracy, specificity, and sensitivity of the method were all found to be in line with ICH guidelines, when the procedure was developed and tested.

Keywords: ICH guide lines, RP-HPLC, Bupropion, Dextromethorphan, validation

How to Cite

Kumar, P. S. and Rambabu, K. (2022) “Development and Validation of a Method for Simultaneous Estimation of Bupropion and Dextromethorphan Using Reverse Phase High Performance Liquid Chromatography in Active Pharmaceutical Ingredient Form”, Journal of Pharmaceutical Research International, 34(52B), pp. 10–19. doi: 10.9734/jpri/2022/v34i52B7217.


Download data is not yet available.


Malhi GS, Byrow Y, Bassett D, Boyce P, Hopwood M, Lyndon W, Mulder R, Porter R, Singh A, Murray G. Stimulants for depression: On the up and up?, Aust N Z J Psychiatry. 2016;50(3):203–7.


Bahji A, Mesbah-Oskui L. Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis, J Affect Disord. 2021;292:416-423.


Huang W, Manglik A, Venkatakrishnan AJ, Laeremans T, Feinberg EN, Sanborn AL et al. Structural insights into µ-opioid receptor activation. Nature. 2015;524 (7565):315–321.


Koehl A, Hu H, Maeda S, Zhang Y, Qu Q, Paggi JM et al. Structure of the µ-opioid receptor-Gi protein complex. Nature. 2018; 558(7711): 547–552.


Morra Mostafa Ebraheem, Elgebaly Ahmed, Elmaraezy Ahmed, Khalil Adham M, Altibi Ahmed MA et al. Therapeutic efficacy and safety of botulinum toxin A therapy in trigeminal neuralgia: A systematic review and meta-analysis of randomized controlled trials, The Journal of Headache and Pain. 2016;17(1):63.


Akyurekli Celine, Le Yevgeniya, Richardson Richard B, Fergusson Dean, Tay Jason, Allan David S. A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. Stem Cell Reviews and Reports.2014;11(1): 150–160.


Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: Relevance to dextro-methorphan/quinidine (Nuedexta®) clinical use. Pharmacology & Therapeutics. 2016;164:170–182.


Volgin Andrey D, Yakovlev Oleg A, Demin Constantin A, Alekseeva Polina A, Kyzar Evan J, Collins Christopher, Nichols David E, Kalueff Allan V. Understanding central nervous system effects of deliriant hallucinogenic drugs through experimental animal models. ACS Chemical Neuro-science. 2019;10(1):143–154.


Sherwood Alexander M, Prisinzano Thomas E. novel psychotherapeutics – a cautiously optimistic focus on hallucinogens. Expert Review of Clinical Pharmacology. 2018;11(1):1–3.


Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity, Br J Anaesth. 2005;95(4):434–41.


Li C, Shan L, Li X, Wei L, Li D. Mifepristone modulates serotonin transporter function. Neural Regen Res. 2014;9(6):646–52.


Brimson JM, Brimson S, Chomchoei C, Tencomnao T. Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain. Expert Opinion on Therapeutic Targets.2020; 24(10): 1009–1028.


Hong W, Werling LL. Evidence that the sigma (1) receptor is not directly coupled to G proteins. European Journal of Pharmacology. 2000;408 (2):117–125.


Bading H. Therapeutic targeting of the pathological triad of extrasynaptic NMDA receptor signaling in neurodegenerations, The Journal of Experimental Medicine. 2017;214(3):569–578.


Garay RP, Zarate CA, Charpeaud T, Citrome L, Correll CU, Hameg A, Llorca PM. Investigational drugs in recent clinical trials for treatment-resistant depression, Expert Rev Neurother. 2017;17(6): 593–609.


Karrouri R, Hammani Z, Benjelloun R, Otheman Y. Major depressive disorder: Validated treatments and future challenges, World J Clin Cases (Review). 2021;9(31):9350–9367.


Swardfager W, Herrmann N, Marzolini S et al. Major depressive disorder predicts completion, adherence and outcomes in cardiac rehabilitation: A prospective cohort study of 195 patients with coronary artery disease. The Journal of Clinical Psychiatry. 2011;72(9):1181–88.


Coughlin LN, Tegge AN, Sheffer CE, Bickel WK. A machine-learning approach to predicting smoking cessation treatment outcomes, Nicotine & Tobacco Research. 2018;22(3):415–422.


Halpern SD, French B, Small DS, Saulsgiver K, Harhay MO, Audrain-McGovern J et al. Randomized trial of four financial-incentive programs for smoking cessation. The New England Journal of Medicine. 2015;372(22):2108–17.


PMC 4471993

Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK. Bupropion: A systematic review and meta-analysis of effectiveness as an antidepressant. Therapeutic Advances in Psychopharma-cology. 2016;6(2):99–144.


Kushida Clete A, Sullivan Shannon S. Multiple sleep latency test and maintenance of wakefulness test. Chest. 2008;134(4):854–861.


Billiard M, Podesta C. Recurrent hypersomnia following traumatic brain injury. Sleep Medicine. 2013;14(5): 462 465.


Billiard M, Dauvilliers Y. Idiopathic hypersomnia. Sleep Med Rev. 2001;5(5): 349–358.


Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. The Journal of Clinical Psychiatry. 2005;66(2): 253–259.


Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: A review for clinicians. The American Journal of Psychiatry. 2014; 171(4):404-415.


Kumar S, Kodela S, Detweiler JG, Kim KY, Detweiler MB. Bupropion-induced psychosis: Folklore or a fact?. A Systematic Review of the literature, General Hospital Psychiatry. 2011;33(6): 612–617.


Nelson JC, Spyker DA. Morbidity and mortality associated with medications used in the treatment of depression: An analysis of cases reported to U.S. poison control centers, 2000-2014. The American Journal of Psychiatry. 2017;174(5):438–450.


De Vries C, Gadzhanova S, Sykes MJ, Ward M, Roughead E. A systematic review and meta-analysis considering the risk for congenital heart defects of antidepressant classes and individual antidepressants. Drug Safety. 2021;44(3):291–312.


Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E et al. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): Focus on antidepressants. The World Journal of Biological Psychiatry. 2021;22(8):561–628.


Gautam M, Patel S, Zarkowski P. Practice patterns of bupropion co-prescription with antipsychotic medications, J Addict Dis: 2022;1–8.